We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Affymetrix Announces Proposed $105 Million Offering of Convertible Senior Notes Due 2019
News

Affymetrix Announces Proposed $105 Million Offering of Convertible Senior Notes Due 2019

Affymetrix Announces Proposed $105 Million Offering of Convertible Senior Notes Due 2019
News

Affymetrix Announces Proposed $105 Million Offering of Convertible Senior Notes Due 2019

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affymetrix Announces Proposed $105 Million Offering of Convertible Senior Notes Due 2019"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Affymetrix Inc., has announced that it intends to offer, subject to market and other considerations, $105 million aggregate principal amount of unsecured Convertible Senior Notes due 2019.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (the “SEC”) and a prospectus supplement filed with the SEC.

Affymetrix also expects to grant the underwriters an option to purchase up to $10 million aggregate principal amount of additional notes on the same terms and conditions, solely to cover over-allotments, if any.

Affymetrix intends to use the net proceeds from the offering to fund a portion of the purchase price for its pending acquisition of eBioscience Holding Company, Inc.

In the event that the acquisition of eBioscience is not consummated and Affymetrix does not elect to redeem the notes, Affymetrix management will retain broad discretion over use of the net proceeds.

Citigroup and Morgan Stanley are acting as joint book-running managers of the offering.

Advertisement